Navigation Links
Avexa's Apricitabine Clinical Trial Update

MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian biotechnology company Avexa (ASX:AVX) announced today the completion of apricitabine's controlled, double blinded phase which represents the first 24 week segment of its Phase IIb trial. Patients have now progressed into the open-label section of the trial (weeks 24 to 48) and will continue to receive 800mg apricitabine twice a day as part of their daily treatment regime. The Company expects to release results from the 24 week blinded phase later this quarter.

Avexa also reported that apricitabine continues to maintain its excellent tolerability profile. To date, 14 patients have completed the full 48 weeks on the trial, and 13 of these have elected to continue on apricitabine treatment in an extension study. The longest treated patient has successfully completed more than 18 months of apricitabine therapy. One additional Serious Adverse Event (hospitalization for a minor surgical procedure) has been reported. However, like the three previously reported, this incident was not associated with study drug.

"This data clearly demonstrates that apricitabine is well tolerated in HIV patients. The number of patients requesting to enter the extension study after the 48 week trial to continue treatment with apricitabine is an indicator of the important role that apricitabine will play in the management of HIV. Apricitabine's clinical development remains on schedule and is demonstrating its potential as a safe and effective treatment for HIV," stated Dr. Julian Chick, CEO of Avexa.

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV and an antibiotic alternative for antibiotic-resistant bact
'"/>




Page: 1 2

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Apricitabine Clinical Trial Update
(Date:8/28/2014)... PORTLAND, Oregon , August 28, 2014 /PRNewswire/ ... Market Research titled, "DNA diagnostics Market (products, applications, ... Analysis, Trends, Opportunities, Growth and Forecast, 2013 - ... would reach $19 billion by 2020 registering a ... potential to provide accurate diagnosis and cost effectiveness ...
(Date:8/28/2014)...  In recognition of the increased risks that ... flu, pneumonia, shingles and other illnesses, CVS/pharmacy ® ... to be Senior Vaccination Month. Because people,s immune ... that adults ages 65 years and older stay ... and MinuteClinic nurse practitioners and physician assistants will ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... Asia-Pacific Markets to 2020 - Novel ... in Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics ...
Breaking Medicine Technology:DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... Ph.D., will join the executive committee of Eli Lilly and ... Walsh will continue in her current role as Lilly,s ... Ph.D., chairman, president, and CEO, and working to ensure Lilly ... Walsh is a recognized thought leader in the ...
... June 30, 2011 Xlumena, Inc., a ... and endoscopic surgeon, announced today that it has received ... The NAVIX is a multi-function system that enables exchange-free ... endoscopic pancreatic pseudocyst drainage.  The NAVIX will join the ...
Cached Medicine Technology:Lilly Quality Leader Walsh Appointed to Company's Executive Committee 2Xlumena Receives CE Mark for NAVIX™, Second Product to Enter European Market 2
(Date:8/29/2014)... The Fresh Diet, America’s premier gourmet meal ... Vegetarian meal plan. Originating from The Fresh Diet’s commitment ... is designed to satisfy customers seeking a convenient, worry-free ... Responding to the growing demand by customers for non-meat ... (Forbes) with 14% of Americans identifying vegetarian meals as ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- The main strain ... Middle East and North Africa originated in sub-Saharan ... so-called community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) ... not recently been hospitalized. These infections typically affect ... contact or through touching contaminated objects such as ...
(Date:8/29/2014)... Parker Waichman LLP, a national law ... rights of victims who have been injured by medications ... new regulations for all hydrocodone combination products. According to ... dated August 21, 2014, the DEA will be regulating ... law. , The long-awaited announcement comes after a ...
(Date:8/29/2014)... 2014 TayganPoint Consulting Group, a leading ... second time, Inc. Magazine has named the company one ... Based on solid revenue growth of over 166% over ... on the list. TayganPoint’s repeat success in this ... past few years, is a demonstration of its strong ...
(Date:8/29/2014)... 2014 Gwyneth Paltrow, Beyonce and Angelina Jolie ... have inspired dieters all over the United States, to find ... to help them quickly shed excess fat. And, recent inspiration ... that substitutes all gluten products, eggs and meats for ingredients ... associated with following this type of diet, one must be ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 3Health News:Diet Doc Announces Diet Plans that Deliver Fast Weight Loss Results at a Fraction of the Cost of Celebrity Diets 2Health News:Diet Doc Announces Diet Plans that Deliver Fast Weight Loss Results at a Fraction of the Cost of Celebrity Diets 3
... Migraine is a neurovascular disease that affects about ... and beverages (chocolate, wine, citrus, etc) considered as ... and phenolic compounds. Avoiding those triggers may ... patients. However, only a small percentage ...
... reduce the use of mechanical ventilation with premature infants ... can profoundly affect those children,s outcomes while reducing the ... at Children,s Hospital Boston. The team, led ... Medicine at Children,s Hospital Boston and the Neonatal Intensive ...
... The American Association for Cancer Research is pleased to ... their families and caregivers won first place in ... of Colon and Rectal Surgeons. Separately, it received three ... the Society of Professional Journalists. "We are ...
... Daytime sleepiness may affect inhibitory control in the ... research abstract that will be presented Monday, June ... 25th Anniversary Meeting of the Associated Professional Sleep ... daytime sleepiness was associated with decreased activation in ...
... insomnia may be able to find relief by wearing a ... abstract that will be presented Monday, June 13, in Minneapolis, ... Associated Professional Sleep Societies LLC (APSS). According to the ... occurs while falling asleep and is associated with restorative sleep. ...
... Multiple Sclerosis sufferers emotional support through group therapy sessions ... NHS almost 500 per patient, a study at The ... planning a larger multi-centre study into the issue to ... MS services currently provided by the NHS. The ...
Cached Medicine News:Health News:The association of alcohol drinking with migraine headache 2Health News:Guidelines for ventilator use help premature infants breathe easier 2Health News:AACR's CR magazine honored with 4 prestigious journalism awards 2Health News:Sleepiness may impair the brain's inhibitory control when viewing high-calorie foods 2Health News:Cooling the brain during sleep may be a natural and effective treatment for insomnia 2Health News:Cooling the brain during sleep may be a natural and effective treatment for insomnia 3Health News:Group therapy helps MS sufferers cope with depression, study finds 2Health News:Group therapy helps MS sufferers cope with depression, study finds 3
... is the least expensive of the series. It has ... central area of the cornea. The model comes with ... a picture of a patients corneal endothelium, you simply ... on the chin rest. The left side of the ...
... The JSZ Orthokeratology (oprifocon ... gas permeable contact lenses used ... temporarily corrects nearsightedness (myopia). The ... and removes them in the ...
... contact lenses used for corneal refractive therapy, ... The patient wears the lenses overnight while ... the day, nearsightedness is corrected or greatly ... contact lenses apply slight pressure to the ...
... Looking for a way to help your ... cardiovascular disease? Based on the outcomes ... Counterpulsation (ECP) has improved the quality of ... perform normal activities of daily living. , ...
Medicine Products: